Compare ServiceNow Inc (NOW) vs TG Therapeutics Inc (TGTX) Price & Performance

ServiceNow (NOW) trades at $127.54, up 0.08% with a bullish technical outlook despite overbought RSI readings. The company demonstrates strong fundamentals with 2025 revenue of $13.28B and net income of $1.75B, though valuation metrics remain elevated with a P/E of 79.71. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while analyst sentiment remains overwhelmingly positive with 87% buy ratings.

ServiceNow presents a compelling growth story with expanding profit margins and strong cash flow generation, though premium valuation and competitive pressures warrant caution. The stock's 41% surge in May 2026 reflects market recognition of AI-driven opportunities, but investors should monitor execution risks and the sustainability of current growth rates amid economic uncertainties.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.